WO2017090039A2 - Pharmaceutical compositions comprising levodopa amide and uses thereof - Google Patents

Pharmaceutical compositions comprising levodopa amide and uses thereof Download PDF

Info

Publication number
WO2017090039A2
WO2017090039A2 PCT/IL2016/051261 IL2016051261W WO2017090039A2 WO 2017090039 A2 WO2017090039 A2 WO 2017090039A2 IL 2016051261 W IL2016051261 W IL 2016051261W WO 2017090039 A2 WO2017090039 A2 WO 2017090039A2
Authority
WO
WIPO (PCT)
Prior art keywords
buffer
acid
pharmaceutical composition
lda
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IL2016/051261
Other languages
English (en)
French (fr)
Other versions
WO2017090039A3 (en
Inventor
Oron Yacoby-Zeevi
Mara Nemes
Eduardo ZWOZNIK
Irena VAINSHTOK
Einat SELA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neuroderm Ltd
Original Assignee
Neuroderm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP2018526784A priority Critical patent/JP2018535230A/ja
Priority to CA3006028A priority patent/CA3006028A1/en
Priority to BR112018010564-3A priority patent/BR112018010564A2/pt
Priority to AU2016358511A priority patent/AU2016358511A1/en
Priority to SG11201804395PA priority patent/SG11201804395PA/en
Priority to RU2018119194A priority patent/RU2018119194A/ru
Priority to EP16816418.4A priority patent/EP3380076A2/en
Priority to CN201680079822.0A priority patent/CN108495617A/zh
Application filed by Neuroderm Ltd filed Critical Neuroderm Ltd
Publication of WO2017090039A2 publication Critical patent/WO2017090039A2/en
Publication of WO2017090039A3 publication Critical patent/WO2017090039A3/en
Priority to IL259484A priority patent/IL259484A/en
Anticipated expiration legal-status Critical
Priority to ZA2018/03485A priority patent/ZA201803485B/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Definitions

  • n is an integer of 1 or more
  • composition is stable for at least 24 hours at room temperature.
  • the present invention relates to a method for treatment of a disease or disorder characterized by neurodegeneration and/or reduced levels of brain dopamine, comprising co-administering to a patient, e.g., an individual, in need thereof (i) a first pharmaceutical composition selected from a pharmaceutical composition A as defined above, provided that said composition does not comprise a decarboxylase inhibitor or a salt thereof, or a pharmaceutical composition C as defined above; and (ii) a second pharmaceutical composition comprising a decarboxylase inhibitor and optionally at least one of a basic amino acid or an amino sugar; and/or a COMT inhibitor; and/or a MAO inhibitor.
  • Fig. 6 depicts LD plasma concentrations following oral administration of 25 mg/kg LD with 10 mg/kg CD in rats.
  • the molar ratio of said LDA compound to said acid is about l: l/n to about 1 :> 1.1, and said composition is stable for at least 24 hours, e.g., for at least 24, 48, 72 or 96 hours, at least 1, 2 or 3 weeks, at least 1, 2 or 3 months, or at least 1 year, at room temperature or at -20 to -80°C.
  • the pharmaceutical composition A of the present invention further comprises a surfactant.
  • Suitable surfactants include, without being limited to, Tween-80, Tween-60, Tween-40, Tween-20, Tween-65, Tween-85, Span 20, Span 40, Span 60, Span 80, Span 85, polyoxyl 35 castor oil (Cremophor EL), polyoxyethylene-660-hydroxystearate (macrogol 660), or Poloxamer 188 (Pluronic ® F-68).
  • Additional one or more pharmaceutically acceptable excipients may be selected from, e.g., N-methylpyrrolidone (NMP), polyvinylpyrrolidone (PVP), and propylene glycol, and added to the composition.
  • NMP N-methylpyrrolidone
  • PVP polyvinylpyrrolidone
  • propylene glycol propylene glycol
  • the present invention provides an aqueous pharmaceutical composition, also referred to herein as "pharmaceutical composition B", having a pH of about 3 to about 9.5, or about 4 to about 8, or about 5 to about 7, or about 5.5 to about 6.5, at 25°C, said composition comprising a salt of a LDA compound of the general formula I as defined above, or an enantiomer, diastereomer, or racemate thereof, a decarboxylase inhibitor or a salt thereof, and at least one of a basic amino acid, e.g., arginine, or an amino sugar, e.g., meglumine, wherein the weight ratio of said decarboxylase inhibitor to said salt of LDA compound is about 1: 1 to about 1: 100, about 1:2 to about 1:60, about 1:4 to about 1:40, or about 1: 10 to about 1:40; and the molar ratio or said decarboxylase inhibitor or salt thereof to said basic amino acid or said amino sugar is about 1:
  • Non-limiting examples of terpenes include d-limonene, dipentene (d/1- limonene), a-pinene, ⁇ -terpinene, ⁇ -mircene, p-cimene, a-pinene, a-phellandrene, citronellolio, geraniale (citrale), nerol, beta-carotene, menthol, geraniol, farnesol, phytol, their homologs, derivatives, enantiomers, isomers including constitutional isomers, stereoisomerisms, regioisomers, and geometric isomers, and any combinations thereof.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Psychology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PCT/IL2016/051261 2015-11-24 2016-11-23 Pharmaceutical compositions comprising levodopa amide and uses thereof Ceased WO2017090039A2 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
EP16816418.4A EP3380076A2 (en) 2015-11-24 2016-11-23 Pharmaceutical compositions comprising levodopa amide and uses thereof
BR112018010564-3A BR112018010564A2 (pt) 2015-11-24 2016-11-23 composições farmacêuticas compreendendo levodopa amida e usos das mesmas
AU2016358511A AU2016358511A1 (en) 2015-11-24 2016-11-23 Pharmaceutical compositions comprising levodopa amide and uses thereof
SG11201804395PA SG11201804395PA (en) 2015-11-24 2016-11-23 Pharmaceutical compositions comprising levodopa amide and uses thereof
RU2018119194A RU2018119194A (ru) 2015-11-24 2016-11-23 Фармацевтические композиции, содержащие амид леводопы, и их применения
JP2018526784A JP2018535230A (ja) 2015-11-24 2016-11-23 レボドパアミドを含む医薬組成物およびその使用
CA3006028A CA3006028A1 (en) 2015-11-24 2016-11-23 Pharmaceutical compositions comprising levodopa amide and uses thereof
CN201680079822.0A CN108495617A (zh) 2015-11-24 2016-11-23 包含左旋多巴酰胺的药物组合物和其用途
IL259484A IL259484A (en) 2015-11-24 2018-05-21 Pharmaceutical compositions comprising levodopa amide and uses thereof
ZA2018/03485A ZA201803485B (en) 2015-11-24 2018-05-25 Pharmaceutical compositions comprising levodopa amide and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562259324P 2015-11-24 2015-11-24
US62/259,324 2015-11-24

Publications (2)

Publication Number Publication Date
WO2017090039A2 true WO2017090039A2 (en) 2017-06-01
WO2017090039A3 WO2017090039A3 (en) 2017-08-31

Family

ID=57590758

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2016/051261 Ceased WO2017090039A2 (en) 2015-11-24 2016-11-23 Pharmaceutical compositions comprising levodopa amide and uses thereof

Country Status (13)

Country Link
US (1) US20170296491A1 (enExample)
EP (1) EP3380076A2 (enExample)
JP (1) JP2018535230A (enExample)
CN (1) CN108495617A (enExample)
AU (1) AU2016358511A1 (enExample)
BR (1) BR112018010564A2 (enExample)
CA (1) CA3006028A1 (enExample)
CL (1) CL2018001395A1 (enExample)
IL (1) IL259484A (enExample)
RU (1) RU2018119194A (enExample)
SG (1) SG11201804395PA (enExample)
WO (1) WO2017090039A2 (enExample)
ZA (1) ZA201803485B (enExample)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10022320B2 (en) 2014-03-13 2018-07-17 Neuroderm, Ltd. Dopa decarboxylase inhibitor compositions
WO2019038639A1 (en) 2017-08-21 2019-02-28 Neuroderm Ltd FREE LEOPODOPA CRYSTALLINE AMIDE BASE AND METHODS OF MAKING AND USING SAME
WO2019038638A1 (en) 2017-08-21 2019-02-28 Neuroderm Ltd PROCESS FOR PREPARING AMIDE OF PURIFIED LEVODOPA
WO2019038637A1 (en) 2017-08-21 2019-02-28 Neuroderm Ltd FORMS OF CRYSTALLINE SALT OF LEVODOPA AMIDE AND METHODS OF MAKING AND USING THEM
US10258585B2 (en) 2014-03-13 2019-04-16 Neuroderm, Ltd. DOPA decarboxylase inhibitor compositions
WO2020178810A1 (en) * 2019-03-04 2020-09-10 Neuroderm, Ltd. Pharmaceutical compositions comprising levodopa amide derivatives and uses thereof
WO2021044420A1 (en) * 2019-09-05 2021-03-11 Neuroderm, Ltd. Liquid compositions comprising a levodopa amino acid conjugate and uses thereof
US11213502B1 (en) 2020-11-17 2022-01-04 Neuroderm, Ltd. Method for treatment of parkinson's disease
US11331293B1 (en) 2020-11-17 2022-05-17 Neuroderm, Ltd. Method for treatment of Parkinson's disease
US11844754B2 (en) 2020-11-17 2023-12-19 Neuroderm, Ltd. Methods for treatment of Parkinson's disease
US12161612B2 (en) 2023-04-14 2024-12-10 Neuroderm, Ltd. Methods and compositions for reducing symptoms of Parkinson's disease

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019145773A1 (en) 2017-12-15 2019-08-01 Nos Life Sciences Corporation Liposomal-encapsulated formulations
US11701340B2 (en) * 2019-04-17 2023-07-18 Vici Health Sciences., Llc Liquid pharmaceutical compositions
JP7506371B2 (ja) * 2020-01-20 2024-06-26 国立大学法人浜松医科大学 ドーパミン減少抑制剤
CN116270675A (zh) * 2023-03-21 2023-06-23 山东省分析测试中心 N-乙酰氨基葡萄糖在防治mptp诱导神经元损伤中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010134074A1 (en) 2009-05-19 2010-11-25 Neuroderm Ltd Compositions for continuous administration of dopa decarboxylase inhibitors
US8048926B2 (en) 2003-02-07 2011-11-01 Yissum Research Development Company Of The Hebrew University Of Jerusalem L-DOPA amide derivatives and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011341316A1 (en) * 2010-12-10 2013-07-04 Synagile Corporation Subcutaneously infusible levodopa prodrug compositions and methods of infusion
US20150217046A1 (en) * 2012-06-05 2015-08-06 Synagile Corporation Dosing regimens for subcutaneously infusible acidic compositions

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8048926B2 (en) 2003-02-07 2011-11-01 Yissum Research Development Company Of The Hebrew University Of Jerusalem L-DOPA amide derivatives and uses thereof
WO2010134074A1 (en) 2009-05-19 2010-11-25 Neuroderm Ltd Compositions for continuous administration of dopa decarboxylase inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CNS NEUROSCIENCE & THERAPEUTICS, vol. 22, 2016, pages 461 - 467

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10813902B2 (en) 2014-03-13 2020-10-27 Neuroderm, Ltd. DOPA decarboxylase inhibitor compositions
US10258585B2 (en) 2014-03-13 2019-04-16 Neuroderm, Ltd. DOPA decarboxylase inhibitor compositions
US10624839B2 (en) 2014-03-13 2020-04-21 Neuroderm, Ltd. Dopa decarboxylase inhibitor compositions
US10022320B2 (en) 2014-03-13 2018-07-17 Neuroderm, Ltd. Dopa decarboxylase inhibitor compositions
WO2019038639A1 (en) 2017-08-21 2019-02-28 Neuroderm Ltd FREE LEOPODOPA CRYSTALLINE AMIDE BASE AND METHODS OF MAKING AND USING SAME
WO2019038638A1 (en) 2017-08-21 2019-02-28 Neuroderm Ltd PROCESS FOR PREPARING AMIDE OF PURIFIED LEVODOPA
WO2019038637A1 (en) 2017-08-21 2019-02-28 Neuroderm Ltd FORMS OF CRYSTALLINE SALT OF LEVODOPA AMIDE AND METHODS OF MAKING AND USING THEM
WO2020178810A1 (en) * 2019-03-04 2020-09-10 Neuroderm, Ltd. Pharmaceutical compositions comprising levodopa amide derivatives and uses thereof
WO2021044420A1 (en) * 2019-09-05 2021-03-11 Neuroderm, Ltd. Liquid compositions comprising a levodopa amino acid conjugate and uses thereof
EP4025200A4 (en) * 2019-09-05 2024-02-07 Neuroderm, Ltd. LIQUID COMPOSITIONS COMPRISING LEVODOPA AMINO ACID CONJUGATE AND USES THEREOF
US11213502B1 (en) 2020-11-17 2022-01-04 Neuroderm, Ltd. Method for treatment of parkinson's disease
US11331293B1 (en) 2020-11-17 2022-05-17 Neuroderm, Ltd. Method for treatment of Parkinson's disease
US11458115B2 (en) 2020-11-17 2022-10-04 Neuroderm, Ltd. Method for treatment of Parkinson's disease
US11844754B2 (en) 2020-11-17 2023-12-19 Neuroderm, Ltd. Methods for treatment of Parkinson's disease
US12161612B2 (en) 2023-04-14 2024-12-10 Neuroderm, Ltd. Methods and compositions for reducing symptoms of Parkinson's disease

Also Published As

Publication number Publication date
IL259484A (en) 2018-07-31
RU2018119194A (ru) 2019-12-25
ZA201803485B (en) 2019-08-28
EP3380076A2 (en) 2018-10-03
CN108495617A (zh) 2018-09-04
RU2018119194A3 (enExample) 2020-04-20
US20170296491A1 (en) 2017-10-19
CA3006028A1 (en) 2017-06-01
WO2017090039A3 (en) 2017-08-31
CL2018001395A1 (es) 2018-10-12
JP2018535230A (ja) 2018-11-29
AU2016358511A1 (en) 2018-06-21
BR112018010564A2 (pt) 2018-11-21
SG11201804395PA (en) 2018-06-28

Similar Documents

Publication Publication Date Title
US20170296491A1 (en) Pharmaceutical compositions comprising levodopa amide and uses thereof
US20230321019A1 (en) Continuous Administration of Dopa Decarboxylase Inhibitors and Compositions for Same
JP6458124B2 (ja) アポモルヒネと有機酸とを含む組成物およびその使用
US20170196828A1 (en) Continuous Administration of Levodopa and/or Dopa Decarboxylase Inhibitors and Compositions for Same
WO2019038638A1 (en) PROCESS FOR PREPARING AMIDE OF PURIFIED LEVODOPA
WO2020178810A1 (en) Pharmaceutical compositions comprising levodopa amide derivatives and uses thereof
EP4305049A1 (en) Stabilized liquid compositions comprising a levodopa-tyrosine conjugate and uses thereof
KR102846332B1 (ko) 레보도파 지방산 유도체, 이의 제형, 및 파킨슨병의 치료를 위한 이들의 사용
WO2020035853A1 (en) Process for preparing purified levodopamide free base
CN116456966A (zh) 含有右旋布洛芬的注射用液态组合物
HK40046868A (en) Compositions for continuous administration of dopa decarboxylase inhibitors
HK1168557B (en) Compositions for continuous administration of dopa decarboxylase inhibitors
HK1168557A (en) Compositions for continuous administration of dopa decarboxylase inhibitors

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16816418

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 259484

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 3006028

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2018526784

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 11201804395P

Country of ref document: SG

Ref document number: MX/A/2018/006444

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112018010564

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 2016358511

Country of ref document: AU

Date of ref document: 20161123

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2018119194

Country of ref document: RU

Ref document number: 2016816418

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2016816418

Country of ref document: EP

Effective date: 20180625

ENP Entry into the national phase

Ref document number: 112018010564

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20180524